Overview

Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Status:
RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab as first-line treatment for patients with RAS mutated or right sided-metastatic MSS colorectal cancer

Phase:

PHASE3

Details

Lead Sponsor:

Caigang Liu

Treatments:

Bevacizumab
Drug Therapy